ParkinsonCanadaV1, Main, Exploration, bibRecord, 004A04

Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis

Identifieur interne : 004A04 ( Main/Exploration ); précédent : 004A03; suivant : 004A05

Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis

Auteurs : E. C. Wolters ; T. A. Hurwitz ; E. Mak ; P. Teal ; F. R. Peppard ; R. Remick ; S. Calne ; D. B. Calne

Source :

Neurology [ 0028-3878 ] ; 1990.

RBID : Pascal:91-0384576

Descripteurs français

Pascal (Inist)
- Psychose toxique, Stimulant dopaminergique, Antiparkinsonien, Clozapine, Neuroleptique, Psychotrope, Toxicité, Parkinson maladie, Maladie dégénérative, Psychiatrie, Système nerveux pathologie, Prévention, Traitement, Homme, Chimiothérapie.
Wicri :
- topic : Psychiatrie, Homme.

English descriptors

KwdEn :
- Aged, Aged, 80 and over, Antiparkinson agent, Chemotherapy, Clozapine (therapeutic use), Degenerative disease, Dibenzazepines (therapeutic use), Dopamine Agents (adverse effects), Dopamine agonist, Double-Blind Method, Female, Human, Humans, Male, Middle Aged, Nervous system diseases, Neuroleptic, Parkinson Disease (drug therapy), Parkinson Disease (psychology), Parkinson disease, Prevention, Psychiatric Status Rating Scales, Psychiatry, Psychoses, Substance-Induced (etiology), Psychoses, Substance-Induced (prevention & control), Psychotropic, Randomized Controlled Trials as Topic, Sleep (drug effects), Toxic psychosis, Toxicity, Treatment.
MESH :
- chemical , adverse effects : Dopamine Agents.
- chemical , therapeutic use : Clozapine, Dibenzazepines.
- drug effects : Sleep.
- drug therapy : Parkinson Disease.
- etiology : Psychoses, Substance-Induced.
- prevention & control : Psychoses, Substance-Induced.
- psychology : Parkinson Disease.
- Aged, Aged, 80 and over, Double-Blind Method, Female, Humans, Male, Middle Aged, Psychiatric Status Rating Scales, Randomized Controlled Trials as Topic.

Abstract

In a double-blind placebo-controlled study, we evaluated the effects of clozapine (75 to 250 mg/day, mean 170.8) on dopaminomimetic psychosis and parkinsonian disability. Clozapine prevented deterioration of psychosis during the increase of dopaminomimetics in the 3 patients who completed the study. Worsening of parkinsonism occurred in 3 of 6 patients

Affiliations:

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis</title>
<author><name sortKey="Wolters, E C" sort="Wolters, E C" uniqKey="Wolters E" first="E. C." last="Wolters">E. C. Wolters</name>
</author>
<author><name sortKey="Hurwitz, T A" sort="Hurwitz, T A" uniqKey="Hurwitz T" first="T. A." last="Hurwitz">T. A. Hurwitz</name>
</author>
<author><name sortKey="Mak, E" sort="Mak, E" uniqKey="Mak E" first="E." last="Mak">E. Mak</name>
</author>
<author><name sortKey="Teal, P" sort="Teal, P" uniqKey="Teal P" first="P." last="Teal">P. Teal</name>
</author>
<author><name sortKey="Peppard, F R" sort="Peppard, F R" uniqKey="Peppard F" first="F. R." last="Peppard">F. R. Peppard</name>
</author>
<author><name sortKey="Remick, R" sort="Remick, R" uniqKey="Remick R" first="R." last="Remick">R. Remick</name>
</author>
<author><name sortKey="Calne, S" sort="Calne, S" uniqKey="Calne S" first="S." last="Calne">S. Calne</name>
</author>
<author><name sortKey="Calne, D B" sort="Calne, D B" uniqKey="Calne D" first="D. B." last="Calne">D. B. Calne</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">91-0384576</idno>
<date when="1990">1990</date>
<idno type="stanalyst">PASCAL 91-0384576 INIST</idno>
<idno type="RBID">Pascal:91-0384576</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001149</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000D78</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">001074</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">001074</idno>
<idno type="wicri:doubleKey">0028-3878:1990:Wolters E:clozapine:in:the</idno>
<idno type="wicri:Area/Main/Merge">005333</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:1970427</idno>
<idno type="wicri:Area/PubMed/Corpus">001B79</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001B79</idno>
<idno type="wicri:Area/PubMed/Curation">001B79</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001B79</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001B79</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001B79</idno>
<idno type="wicri:Area/Ncbi/Merge">000B35</idno>
<idno type="wicri:Area/Ncbi/Curation">000B35</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000B35</idno>
<idno type="wicri:doubleKey">0028-3878:1990:Wolters E:clozapine:in:the</idno>
<idno type="wicri:Area/Main/Merge">005174</idno>
<idno type="wicri:Area/Main/Curation">004A04</idno>
<idno type="wicri:Area/Main/Exploration">004A04</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis</title>
<author><name sortKey="Wolters, E C" sort="Wolters, E C" uniqKey="Wolters E" first="E. C." last="Wolters">E. C. Wolters</name>
</author>
<author><name sortKey="Hurwitz, T A" sort="Hurwitz, T A" uniqKey="Hurwitz T" first="T. A." last="Hurwitz">T. A. Hurwitz</name>
</author>
<author><name sortKey="Mak, E" sort="Mak, E" uniqKey="Mak E" first="E." last="Mak">E. Mak</name>
</author>
<author><name sortKey="Teal, P" sort="Teal, P" uniqKey="Teal P" first="P." last="Teal">P. Teal</name>
</author>
<author><name sortKey="Peppard, F R" sort="Peppard, F R" uniqKey="Peppard F" first="F. R." last="Peppard">F. R. Peppard</name>
</author>
<author><name sortKey="Remick, R" sort="Remick, R" uniqKey="Remick R" first="R." last="Remick">R. Remick</name>
</author>
<author><name sortKey="Calne, S" sort="Calne, S" uniqKey="Calne S" first="S." last="Calne">S. Calne</name>
</author>
<author><name sortKey="Calne, D B" sort="Calne, D B" uniqKey="Calne D" first="D. B." last="Calne">D. B. Calne</name>
</author>
</analytic>
<series><title level="j" type="main">Neurology</title>
<title level="j" type="abbreviated">Neurology</title>
<idno type="ISSN">0028-3878</idno>
<imprint><date when="1990">1990</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Neurology</title>
<title level="j" type="abbreviated">Neurology</title>
<idno type="ISSN">0028-3878</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term>
<term>Aged, 80 and over</term>
<term>Antiparkinson agent</term>
<term>Chemotherapy</term>
<term>Clozapine (therapeutic use)</term>
<term>Degenerative disease</term>
<term>Dibenzazepines (therapeutic use)</term>
<term>Dopamine Agents (adverse effects)</term>
<term>Dopamine agonist</term>
<term>Double-Blind Method</term>
<term>Female</term>
<term>Human</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Nervous system diseases</term>
<term>Neuroleptic</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (psychology)</term>
<term>Parkinson disease</term>
<term>Prevention</term>
<term>Psychiatric Status Rating Scales</term>
<term>Psychiatry</term>
<term>Psychoses, Substance-Induced (etiology)</term>
<term>Psychoses, Substance-Induced (prevention & control)</term>
<term>Psychotropic</term>
<term>Randomized Controlled Trials as Topic</term>
<term>Sleep (drug effects)</term>
<term>Toxic psychosis</term>
<term>Toxicity</term>
<term>Treatment</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Dopamine Agents</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Clozapine</term>
<term>Dibenzazepines</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Sleep</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Psychoses, Substance-Induced</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Psychoses, Substance-Induced</term>
</keywords>
<keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Aged, 80 and over</term>
<term>Double-Blind Method</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Psychiatric Status Rating Scales</term>
<term>Randomized Controlled Trials as Topic</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Psychose toxique</term>
<term>Stimulant dopaminergique</term>
<term>Antiparkinsonien</term>
<term>Clozapine</term>
<term>Neuroleptique</term>
<term>Psychotrope</term>
<term>Toxicité</term>
<term>Parkinson maladie</term>
<term>Maladie dégénérative</term>
<term>Psychiatrie</term>
<term>Système nerveux pathologie</term>
<term>Prévention</term>
<term>Traitement</term>
<term>Homme</term>
<term>Chimiothérapie</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Psychiatrie</term>
<term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">In a double-blind placebo-controlled study, we evaluated the effects of clozapine (75 to 250 mg/day, mean 170.8) on dopaminomimetic psychosis and parkinsonian disability. Clozapine prevented deterioration of psychosis during the increase of dopaminomimetics in the 3 patients who completed the study. Worsening of parkinsonism occurred in 3 of 6 patients</div>
</front>
</TEI>
<affiliations><list></list>
<tree><noCountry><name sortKey="Calne, D B" sort="Calne, D B" uniqKey="Calne D" first="D. B." last="Calne">D. B. Calne</name>
<name sortKey="Calne, S" sort="Calne, S" uniqKey="Calne S" first="S." last="Calne">S. Calne</name>
<name sortKey="Hurwitz, T A" sort="Hurwitz, T A" uniqKey="Hurwitz T" first="T. A." last="Hurwitz">T. A. Hurwitz</name>
<name sortKey="Mak, E" sort="Mak, E" uniqKey="Mak E" first="E." last="Mak">E. Mak</name>
<name sortKey="Peppard, F R" sort="Peppard, F R" uniqKey="Peppard F" first="F. R." last="Peppard">F. R. Peppard</name>
<name sortKey="Remick, R" sort="Remick, R" uniqKey="Remick R" first="R." last="Remick">R. Remick</name>
<name sortKey="Teal, P" sort="Teal, P" uniqKey="Teal P" first="P." last="Teal">P. Teal</name>
<name sortKey="Wolters, E C" sort="Wolters, E C" uniqKey="Wolters E" first="E. C." last="Wolters">E. C. Wolters</name>
</noCountry>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004A04 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004A04 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     Pascal:91-0384576
   |texte=   Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis
}}

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

La maladie de Parkinson au Canada (serveur d'exploration)

Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis

Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.